Fluence LED Solutions Pave the Way for Optimizing Success in Urban Medicinal Cannabis Grow
10.5.2023 15:30:00 EEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its success in supporting Trichome, an Israeli facility growing world-class medicinal cannabis, to prove the concept of two-tiered vertical farming in an urban center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005315/en/
Fluence LEDs inside Trichome's urban facility have supported 17 full crop growing cycles, all with greater than expected results. (Photo: Business Wire)
To successfully launch an urban vertical growing facility in Qiryat Gat, Israel, Trichome needed to collaborate with the right solution partners to maximize space while optimizing quality and automation at every step of the process. To appropriately design for the compact, intricate indoor environment and complexities associated with tiered growing, Trichome turned to Fluence for its market-leading LED lighting solutions, local service capabilities through Fluence's Israeli distribution partner, REMY, and in-house horticultural experts to assist with planning, installing and managing the deployment of integrated lighting technology.
“By partnering with Fluence, we were not reinventing the wheel but choosing the best wheels in the market,” said Tony Levi, co-founder and CEO of Trichome. “Standardization, longevity and optimization are critical factors in producing high-quality cannabis flowers. The team of experts at Fluence helped us accomplish all of those goals in an urban farm within city limits.”
Trichome installed Fluence lighting throughout its fully standardized medicinal cannabis facility. To overcome the obstacles presented by a reduction in space between crops and the artificial lights in vertical farms, Fluence worked closely with REMY, Levi and the Trichome team to understand the facility’s constraints. Ultimately, Fluence designed a bespoke system comprising its SPYDR 2i, SPYDR 2x and RAZR Modular series for Trichome. Trichome has completed 17 full crop growing cycles, all with greater than expected results using Fluence lighting—including above average yields, higher than expected terpene levels and high cannabinoid content.
“We are thrilled by the response of our plants to the Fluence LED lighting,” said Steve Abboud, head grower at Trichome. “Our cannabis crops are taking in the light from Fluence fixtures and expressing its quality through their flowering. We have been able to standardize light intensity, harness control over our cultivation methods and achieve crop uniformity because of Fluence LEDs.”
“Working with Trichome on lighting solutions has been an exciting and ambitious process where both parties learned a tremendous amount,” said Jörg Meyer-Brenken, lead account manager, cannabis EMEA at Fluence. “The product Trichome supplies is outstanding, but the feedback from the market and patients makes me even prouder. Trichome has been able to set a new bar for urban farming.”
Fluence LED lighting solutions are available for purchase by licensed cultivators in territories in which the cultivation of cannabis is legal.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, integration and quality assurance of large-scale agronomic lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, today, it also provides agronomic lighting training at its headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow.
About Trichome
Trichome is an Israeli agritech company that combines two complementary worlds—quality cannabis agriculture and advanced cannabis technologies. The company philosophy is based on three main pillars: Indoor Growth by Advanced Technology, an international team of cannabis experts and the finest, high-end varieties. Trichome owns the largest Indoor facility for medical cannabis cultivation in the Middle East. With nine flowering rooms, the multilayer facility is spread over 7,000 square meters and has an annual production capacity of six tons of high-quality, consistent standardized inflorescence. Trichome works through several channels including its own brand and white label. For more information, visit www.trichome-il.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005315/en/
Contact information
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 (0) 160 93335045
For North America,
Callie Neatherlin
Red Fan Communications
callie@redfancommunications.com
512-439-9720
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release
Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release
ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
